Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats

We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of immunology (1950) 2001-10, Vol.167 (8), p.4651-4660
Hauptverfasser: Abe, Masayoshi, Shibata, Kazuhiko, Akatsu, Hiroyasu, Shimizu, Naomi, Sakata, Noriyuki, Katsuragi, Takeshi, Okada, Hidechika
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4660
container_issue 8
container_start_page 4651
container_title The Journal of immunology (1950)
container_volume 167
creator Abe, Masayoshi
Shibata, Kazuhiko
Akatsu, Hiroyasu
Shimizu, Naomi
Sakata, Noriyuki
Katsuragi, Takeshi
Okada, Hidechika
description We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.
doi_str_mv 10.4049/jimmunol.167.8.4651
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72180467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18116836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</originalsourceid><addsrcrecordid>eNqFkc2O0zAURi0EYsrAEyAhr2CV4p_YSZZRNcMgVUIawdq6TW9ajxw72I4yfXtStSPYsbKufL6zOYR85GxdsrL5-mSHYfLBrbmu1vW61Iq_IiuuFCu0Zvo1WTEmRMErXd2Qdyk9McY0E-VbcsO5anjVqBXxm-BztLsp2-Bp6GnrYTyeHOTwbD3dKKA50C1kpK2NM5zoI6Yx-ISJtn3GuNwjLt97evc8hjRFvFiyPaA_b1vnMB5sRx8hp_fkTQ8u4Yfre0t-3d_93DwU2x_fvm_abdGVlcoFAEPVlAiCs3onRQcoBJNaS9b10DRdr2pQgqsd56ICJhVCB3IvodblXjTylny-eMcYfk-Yshls6tA58BimZCrBa1bq6r8grznXtdQLKC9gF0NKEXszRjtAPBnOzLmHeelhlh6mNucey-rTVT_tBtz_3VwDLMCXC3C0h-NsI5o0gHMLzs08z_-o_gCaJZbS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18116836</pqid></control><display><type>article</type><title>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Abe, Masayoshi ; Shibata, Kazuhiko ; Akatsu, Hiroyasu ; Shimizu, Naomi ; Sakata, Noriyuki ; Katsuragi, Takeshi ; Okada, Hidechika</creator><creatorcontrib>Abe, Masayoshi ; Shibata, Kazuhiko ; Akatsu, Hiroyasu ; Shimizu, Naomi ; Sakata, Noriyuki ; Katsuragi, Takeshi ; Okada, Hidechika</creatorcontrib><description>We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.167.8.4651</identifier><identifier>PMID: 11591795</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject><![CDATA[Airway Resistance ; Anaphylatoxin C5a ; Animals ; Antigens - administration & dosage ; Antigens - immunology ; Antigens, CD - genetics ; Antigens, CD - isolation & purification ; Asthma - drug therapy ; Asthma - etiology ; Asthma - immunology ; Bronchi - pathology ; Bronchoalveolar Lavage Fluid - cytology ; Chemokine CCL11 ; Chemokines, CC ; Chemokines, CXC ; Chemotactic Factors ; Complement C3a - analogs & derivatives ; Complement C3a - pharmacology ; Complement C5a - immunology ; Complement C5a, des-Arginine - pharmacology ; complement receptor 1 ; Cytokines - genetics ; Cytokines - isolation & purification ; Growth Substances ; Guanidines - therapeutic use ; Hypersensitivity - drug therapy ; Hypersensitivity - etiology ; Hypersensitivity - immunology ; Intercellular Signaling Peptides and Proteins ; Lung - immunology ; Membrane Proteins ; Ovalbumin - administration & dosage ; Ovalbumin - immunology ; Rats ; Receptor, Anaphylatoxin C5a ; Receptors, Complement - genetics ; Receptors, Complement - isolation & purification ; Receptors, Complement 3b - therapeutic use ; RNA, Messenger - isolation & purification]]></subject><ispartof>The Journal of immunology (1950), 2001-10, Vol.167 (8), p.4651-4660</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</citedby><cites>FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11591795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abe, Masayoshi</creatorcontrib><creatorcontrib>Shibata, Kazuhiko</creatorcontrib><creatorcontrib>Akatsu, Hiroyasu</creatorcontrib><creatorcontrib>Shimizu, Naomi</creatorcontrib><creatorcontrib>Sakata, Noriyuki</creatorcontrib><creatorcontrib>Katsuragi, Takeshi</creatorcontrib><creatorcontrib>Okada, Hidechika</creatorcontrib><title>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.</description><subject>Airway Resistance</subject><subject>Anaphylatoxin C5a</subject><subject>Animals</subject><subject>Antigens - administration &amp; dosage</subject><subject>Antigens - immunology</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - isolation &amp; purification</subject><subject>Asthma - drug therapy</subject><subject>Asthma - etiology</subject><subject>Asthma - immunology</subject><subject>Bronchi - pathology</subject><subject>Bronchoalveolar Lavage Fluid - cytology</subject><subject>Chemokine CCL11</subject><subject>Chemokines, CC</subject><subject>Chemokines, CXC</subject><subject>Chemotactic Factors</subject><subject>Complement C3a - analogs &amp; derivatives</subject><subject>Complement C3a - pharmacology</subject><subject>Complement C5a - immunology</subject><subject>Complement C5a, des-Arginine - pharmacology</subject><subject>complement receptor 1</subject><subject>Cytokines - genetics</subject><subject>Cytokines - isolation &amp; purification</subject><subject>Growth Substances</subject><subject>Guanidines - therapeutic use</subject><subject>Hypersensitivity - drug therapy</subject><subject>Hypersensitivity - etiology</subject><subject>Hypersensitivity - immunology</subject><subject>Intercellular Signaling Peptides and Proteins</subject><subject>Lung - immunology</subject><subject>Membrane Proteins</subject><subject>Ovalbumin - administration &amp; dosage</subject><subject>Ovalbumin - immunology</subject><subject>Rats</subject><subject>Receptor, Anaphylatoxin C5a</subject><subject>Receptors, Complement - genetics</subject><subject>Receptors, Complement - isolation &amp; purification</subject><subject>Receptors, Complement 3b - therapeutic use</subject><subject>RNA, Messenger - isolation &amp; purification</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAURi0EYsrAEyAhr2CV4p_YSZZRNcMgVUIawdq6TW9ajxw72I4yfXtStSPYsbKufL6zOYR85GxdsrL5-mSHYfLBrbmu1vW61Iq_IiuuFCu0Zvo1WTEmRMErXd2Qdyk9McY0E-VbcsO5anjVqBXxm-BztLsp2-Bp6GnrYTyeHOTwbD3dKKA50C1kpK2NM5zoI6Yx-ISJtn3GuNwjLt97evc8hjRFvFiyPaA_b1vnMB5sRx8hp_fkTQ8u4Yfre0t-3d_93DwU2x_fvm_abdGVlcoFAEPVlAiCs3onRQcoBJNaS9b10DRdr2pQgqsd56ICJhVCB3IvodblXjTylny-eMcYfk-Yshls6tA58BimZCrBa1bq6r8grznXtdQLKC9gF0NKEXszRjtAPBnOzLmHeelhlh6mNucey-rTVT_tBtz_3VwDLMCXC3C0h-NsI5o0gHMLzs08z_-o_gCaJZbS</recordid><startdate>20011015</startdate><enddate>20011015</enddate><creator>Abe, Masayoshi</creator><creator>Shibata, Kazuhiko</creator><creator>Akatsu, Hiroyasu</creator><creator>Shimizu, Naomi</creator><creator>Sakata, Noriyuki</creator><creator>Katsuragi, Takeshi</creator><creator>Okada, Hidechika</creator><general>Am Assoc Immnol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20011015</creationdate><title>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</title><author>Abe, Masayoshi ; Shibata, Kazuhiko ; Akatsu, Hiroyasu ; Shimizu, Naomi ; Sakata, Noriyuki ; Katsuragi, Takeshi ; Okada, Hidechika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-aa0e594ea2108b32cae22036630cfa99cf58a5215b1127a035eaca3d3a864d293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Airway Resistance</topic><topic>Anaphylatoxin C5a</topic><topic>Animals</topic><topic>Antigens - administration &amp; dosage</topic><topic>Antigens - immunology</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - isolation &amp; purification</topic><topic>Asthma - drug therapy</topic><topic>Asthma - etiology</topic><topic>Asthma - immunology</topic><topic>Bronchi - pathology</topic><topic>Bronchoalveolar Lavage Fluid - cytology</topic><topic>Chemokine CCL11</topic><topic>Chemokines, CC</topic><topic>Chemokines, CXC</topic><topic>Chemotactic Factors</topic><topic>Complement C3a - analogs &amp; derivatives</topic><topic>Complement C3a - pharmacology</topic><topic>Complement C5a - immunology</topic><topic>Complement C5a, des-Arginine - pharmacology</topic><topic>complement receptor 1</topic><topic>Cytokines - genetics</topic><topic>Cytokines - isolation &amp; purification</topic><topic>Growth Substances</topic><topic>Guanidines - therapeutic use</topic><topic>Hypersensitivity - drug therapy</topic><topic>Hypersensitivity - etiology</topic><topic>Hypersensitivity - immunology</topic><topic>Intercellular Signaling Peptides and Proteins</topic><topic>Lung - immunology</topic><topic>Membrane Proteins</topic><topic>Ovalbumin - administration &amp; dosage</topic><topic>Ovalbumin - immunology</topic><topic>Rats</topic><topic>Receptor, Anaphylatoxin C5a</topic><topic>Receptors, Complement - genetics</topic><topic>Receptors, Complement - isolation &amp; purification</topic><topic>Receptors, Complement 3b - therapeutic use</topic><topic>RNA, Messenger - isolation &amp; purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abe, Masayoshi</creatorcontrib><creatorcontrib>Shibata, Kazuhiko</creatorcontrib><creatorcontrib>Akatsu, Hiroyasu</creatorcontrib><creatorcontrib>Shimizu, Naomi</creatorcontrib><creatorcontrib>Sakata, Noriyuki</creatorcontrib><creatorcontrib>Katsuragi, Takeshi</creatorcontrib><creatorcontrib>Okada, Hidechika</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abe, Masayoshi</au><au>Shibata, Kazuhiko</au><au>Akatsu, Hiroyasu</au><au>Shimizu, Naomi</au><au>Sakata, Noriyuki</au><au>Katsuragi, Takeshi</au><au>Okada, Hidechika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2001-10-15</date><risdate>2001</risdate><volume>167</volume><issue>8</issue><spage>4651</spage><epage>4660</epage><pages>4651-4660</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>11591795</pmid><doi>10.4049/jimmunol.167.8.4651</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1767
ispartof The Journal of immunology (1950), 2001-10, Vol.167 (8), p.4651-4660
issn 0022-1767
1550-6606
language eng
recordid cdi_proquest_miscellaneous_72180467
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Airway Resistance
Anaphylatoxin C5a
Animals
Antigens - administration & dosage
Antigens - immunology
Antigens, CD - genetics
Antigens, CD - isolation & purification
Asthma - drug therapy
Asthma - etiology
Asthma - immunology
Bronchi - pathology
Bronchoalveolar Lavage Fluid - cytology
Chemokine CCL11
Chemokines, CC
Chemokines, CXC
Chemotactic Factors
Complement C3a - analogs & derivatives
Complement C3a - pharmacology
Complement C5a - immunology
Complement C5a, des-Arginine - pharmacology
complement receptor 1
Cytokines - genetics
Cytokines - isolation & purification
Growth Substances
Guanidines - therapeutic use
Hypersensitivity - drug therapy
Hypersensitivity - etiology
Hypersensitivity - immunology
Intercellular Signaling Peptides and Proteins
Lung - immunology
Membrane Proteins
Ovalbumin - administration & dosage
Ovalbumin - immunology
Rats
Receptor, Anaphylatoxin C5a
Receptors, Complement - genetics
Receptors, Complement - isolation & purification
Receptors, Complement 3b - therapeutic use
RNA, Messenger - isolation & purification
title Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T10%3A54%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20Anaphylatoxin%20C5a%20to%20Late%20Airway%20Responses%20After%20Repeated%20Exposure%20of%20Antigen%20to%20Allergic%20Rats&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Abe,%20Masayoshi&rft.date=2001-10-15&rft.volume=167&rft.issue=8&rft.spage=4651&rft.epage=4660&rft.pages=4651-4660&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.167.8.4651&rft_dat=%3Cproquest_cross%3E18116836%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18116836&rft_id=info:pmid/11591795&rfr_iscdi=true